Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review discusses proof of the concept pre-clinical studies and phase-I/II human trials using VEGF, and cellular angiogenesis at length in the light of the literature and analyzes the problems and considerations of these approaches as a treatment strategy in the clinical perspective for the treatment of ischemic heart disease.
|
14963670 |
2004 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent experiments performed in this same porcine model of myocardial ischemia have shown that direct intramyocardial gene transfer of naked plasmid DNA encoding VEGF (phVEGF(165), the identical plasmid used in our previous animal and human clinical trials) can be safely and successfully achieved through a minimally invasive chest wall incision.
|
10426872 |
1999 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is an important active protein for the induction of angiogenesis and improvement in cardiac function after myocardial ischemia; however, the lack of a delivery system targeted to the injured myocardium reduces the local therapeutic efficacy of VEGF and increases its possible adverse effects.
|
19307480 |
2009 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia.
|
20607367 |
2010 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study does not provide strong evidence for a positive effect of VEGF on IHD but does not rule out the possibility that some specific types of VEGF, for which genetic predictors have not yet been identified, might play a role.
|
28765276 |
2017 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neovascularization stimulated by VEGF occurs in several important clinical contexts, including myocardial ischemia, retinal disease, and tumor growth.
|
8756616 |
1996 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This in vitro study explored the effect of VEGF and serum deprivation on endothelial differentiation capacity of ASCs from healthy donors and IHD patients.
|
24047149 |
2013 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, VEGF microparticles and CoQ10 nanoparticles can be considered as promising strategies for managing MI.
|
23639291 |
2013 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, therapeutic angiogenesis using the vascular endothelial growth factor gene was applied in the treatment of ischemic heart disease.
|
11728604 |
2001 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Encouraging results have been obtained with the angiogenic cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor in animal models, leading to clinical trials in ischemic heart disease.
|
11711525 |
2001 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, with the localized induction of VEGF and the low cytotoxicity of WSLP, the pEpo-SV-VEGF/WSLP system may be helpful to eventually treat ischemic heart disease.
|
12907944 |
2003 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymosin beta-4 (TB4) and vascular endothelial growth factor (VEGF) are linked to adult epicardial progenitor cell mobilization and neovascularization and is cardioprotective after myocardial ischemia.
|
21332365 |
2011 |
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is not clear whether treatment by vascular endothelial growth factor (VEGF) gene transfer can improve myocardial ischemia through a proangiogenesis mechanism and is effective against coronary artery disease (CAD).
|
30035366 |
2018 |
Myocardial Ischemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the dog heart, an important model for studies of myocardial ischemia and angiogenesis, the expression of VEGF remains to be established.
|
11195786 |
2000 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this brief review, the role of a prime angiogenic candidate, namely vascular endothelial growth factor (VEGF) and its homologues, in physiological and pathological angiogenesis will be discussed with particular attention to myocardial ischemia and heart failure.
|
10865845 |
2000 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, therapeutic angiogenesis using the VEGF gene has been used to treat ischemic heart disease since 1997.
|
12499610 |
2002 |
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AdGVVEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 10(8) to 4 x 10(9.5) PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease.
|
10400771 |
1999 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of application of vascular endothelial growth factor (VEGF) GT strategies for therapeutic angiogenesis in critical limb and myocardial ischemia in pilot clinical trials was reviewed.
|
11773594 |
2001 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The central role of vascular endothelial growth factor (VEGF) in angiogenesis in health and disease makes it attractive both as a therapeutic target for anti-angiogenic drugs and as a pro-angiogenic cytokine for the treatment of ischaemic heart disease.
|
11166270 |
2001 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that controlled homogeneous VEGF delivery by FACS-purified transduced ASC is a promising strategy to achieve safe and functional angiogenesis in myocardial ischaemia.
|
29478261 |
2018 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia.
|
9860779 |
1999 |
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analyses indicated that the strongest associations with IHD and MI were due to the combined effect of the VEGFA-2578 A allele and smoking (OR 3.52 and 7.11, respectively), independent of risk factors such as age, sex, diabetes, C-reactive protein, hypercholesterolemia, and hypertension.
|
21362767 |
2011 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1.
|
18373738 |
2008 |
Myocardial Ischemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because hypoxia-inducible factor (HIF)-1alpha is a transcriptional activator of vascular endothelial growth factor (VEGF) and is critical for initiating angiogenic responses to hypoxia, we investigated the expression of HIF-1alpha and VEGF in specimens of human heart tissue to elucidate the molecular responses to myocardial ischemia in diabetic patients during unstable angina.
|
15331549 |
2004 |
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mobilization of endothelial progenitor cells with cytokines potentiates VEGF-2 gene therapy for myocardial ischemia and enhances bone marrow cell incorporation into ischemic myocardium.
|
15337699 |
2004 |